Gw Pharma Limited

Otsuka Pharmaceutical Company, Limited

Gw Research Limited

Epitech Group S.r.l.

Allergan, Inc.

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Indena S.p.a.

Consiglio Nazionale Delle Richerche

Innovet Italia S.r.l.

Epitech Group S.p.a.

Vincenzo Di Marzo

Colin Stott

Luciano De Petrocellis

Francesco Della Valle

Geoffrey W Guy

Stephen Wright

Maria Federica Della Valle

Gabriele Marcolongo

Tetsuro Kikuchi

Daniela Parolaro

Alan Sutton

Mar Lorente

Sofia Torres

Etienne De Meijer

Angelo Antonio Izzo

Guillermo Velasco

David Potter

Paola Massi

Gabriella Aviello

Aniello Schiano Moriello

Alessia Ligresti

Ruth Alexandra Ross

Lesley Ann Ford

Sharon Anavi-Goffer

Manuel Guzman

Paolo Morazzoni

Raphael Mechoulam

Gabriele Fontana

Antonella Riva

Giovanni Appendino

Salvatore Cuzzocrea

Keith Foster

Marnie Duncan

Linda Parker

Francesca Borrelli

Federica Della Valle

Teresa Iuvone

Fabio Iannotti

Cristoforo Silvestri

Rami Yaka

Andrea Martella

Francesca Borelli

Sabatino Maione

Sabatino Malone

Vito De Novellis

Fabiana Piscitelli

Tiziana Bisogno

Dominique Melck

Stefania Petrosino

Barbara Costa

Daniele Grassi

Aron H Lichtman

Tamás Biró

Imad M Damaj

Gianpiero Ravagnan

Paolo Indena SpA Morazzoni

Antonella Indena SpA Riva

Gabriele Indena SpA Fontana

Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.

Use of a combination of Adelmidrol and hyaluronic acid in the treatment of pain caused by osteoarthritis and epithelial dysfunctions

The present invention relates to the use of one or more cannabinoids in the treatment of an inflammatory skin disease. Preferably the one or more cannabinoids are taken from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV). The inflammatory skin disease may be caused by one or more of the following: microbial infection-induced dermatitis; solar dermatitis; atopic dermatitis; and allergic contact dermatitis.

Use of cannabinoids in the treatment of inflammatory skin diseases

The present invention is directed to a fatty acid amide of an amino acid, including a stereoisomer and a salt thereof for use in the treatment of a patient suffering from any type of addiction disorder, substance abuse disorder, including any condition and symptom associated therewith and including withdrawal syndrome and relapse addiction during and after a rehabilitation treatment of said patient.

Fatty acid amides and uses thereof in the treatment of addiction disorder and addiction related conditions

The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.

Cannabinoids for use in the treatment of neurodegenerative diseases or disorders

The present invention relates to the use of cannabinoids in the treatment of degenerative skeletal muscle disease. In particular the degenerative skeletal muscle disease is Duchenne muscular dystrophy (DMD). Preferably the cannabinoids are one or more of: Cannabidiol (CBD); Cannabidivarin (CBDV); and Tetrahydrocannabivarin (THCV).

Use of cannabinoids in the treatment of degenerative skeletal muscle diseases

The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention relates to the use of 7-hydroxy-cannabidiol (7-OH-CBD) in the treatment of non-alcoholic fatty liver disease (NAFLD). Treatment of NAFLD involves lowering the triglyceride levels in a patient's blood stream.

7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)

This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.

Phytocannabinoids in the treatment of cancer

The present invention regards compositions and methods for the modulation of amidases capable of hydrolyzing N-acylethanolamines useable in the therapy of inflammatory diseases. In particular, the present invention regards a compound of general formula (I): enantiomers, diastereoisomers, racemes and mixtures, polymorphs, salts, solvates thereof, wherein: (a) R is a linear alkyl radical having 13 to 19 carbon atoms or alkenyl radical having 13 to 19 carbon atoms carrying a double bond; (b) X is 0 or S; (c) Y is a 2 or 3 carbon atom alkylene residue, optionally substituted with one or two groups equal or different from each other and selected from among the group consisting of: &#x2014;CH, &#x2014;CHOH, &#x2014;COOCH, &#x2014;COOH. Y may preferably be: &#x2014;CH&#x2014;CH&#x2014;, &#x2014;CH&#x2014;CH&#x2014;CH&#x2014;, CH(CH)&#x2014;CH&#x2014;, &#x2014;CH&#x2014;CH(CH)&#x2014;, &#x2014;CH&#x2014;C(CH)&#x2014;, &#x2014;CH&#x2014;CH(CHOH)&#x2014;, &#x2014;CH&#x2014;C((CHOH))&#x2014;, &#x2014;CH&#x2550;CH&#x2014;, &#x2014;CH&#x2014;CH(COOCH)&#x2014;, &#x2014;CH&#x2014;CH(COOH)&#x2014;, for use as a medicine. 

Compositions and methods for the modulation of specific amidases for N-acylethanolamines for use in the therapy of inflammatory diseases

The present invention relates to topical preparations containing N-palmitoyl-vanillamide having hyperalgesic activity. In particular, the invention relates to N-palmitoyl-vanillamide for use in the treatment of pathologies selected from: post-herpetic neuralgia, neuralgia of trigeminus, occipital neuralgia, dental neuralgia, glottopharyngeal neuralgia, uremic neuralgia, diabetic neuralgia, headache of different origin, neuropathic itch, neurogenic itch, uremic itch, vulvodinia, vulvar vestibulitis, ano-rectal pain and itch, balano-preputial pain and itch, painful urogenital disorders of dogs and cats, psoriasis-associated pruritus and pain, itching skin diseases (e.g. atopic dermatitis) in the human and veterinary field, muscular pain, pain of the tendon, osteoarthritis associated pain in humans, dogs and cats; painful eye diseases in the human and veterinary field, inflammatory pathologies of the oral cavity in the human and veterinary field.

Pharmacological preparation for topical use containing N-palmitoyl-vanillamide

The present invention provides pharmaceutical compositions useful in a method for treating neuropathic pain, said method comprising administration of a pain-ameliorating effective amount of the compound according to formula I wherein R is an alk(en)yl group, R1 is an alkylen(yl) group, n is 0 or 1 and Ar is a carbocyclic aryl group.

Method for treating pain

The compounds of the general formula (I) in which X is represents two hydrogen atoms, a &#x3c0;-bond, oxygen or methylene: R2 is a C-Caryl, or arylalkyl residue: R3 is hydrogen, 2-hydroxyethyl or 2-aminoethyl are useful for the treatment of pathologies mediated by vanilloid receptors type I. 

TRPV1 agonists, formulations containing them and uses thereof

The present invention relates to the use of N-acylvanillinamide derivatives capable of activating the peripheral receptor CB1 of cannabinoids. In particular, the present invention relates to the use of compounds of general formula (I) in which the meanings of R, R, Rand Y are as defined in the description, for the preparation of a medicinal product which is capable of activating the peripheral receptor CB1 of cannabinoids.

N-acylvanillinamide derivatives capable of activating peripheral cannabinoid receptors

Growing community of inventors

Naples, Italy

Vincenzo Di Marzo